Final results from ACIS, a randomized, placebo (PBO)-controlled double-blind phase 3 study of apalutamide (APA) and abiraterone acetate plus prednisone (AAP) versus AAP in patients (pts) with chemo-naive metastatic castration-resistant prostate cancer (mCRPC) Meeting Abstract
| Authors: | Rathkopf, D. E.; Efstathiou, E.; Attard, G.; Flaig, T. W.; Franke, F. A.; Goodman, O. B.; Oudard, S.; Steuber, T.; Suzuki, H.; Wu, D.; Yeruva, K.; De Porre, P.; Brookman-May, S. D.; Li, S.; Li, J.; Mundle, S.; McCarthy, S. A.; Saad, F.; on behalf of the ACIS investigators |
| Abstract Title: | Final results from ACIS, a randomized, placebo (PBO)-controlled double-blind phase 3 study of apalutamide (APA) and abiraterone acetate plus prednisone (AAP) versus AAP in patients (pts) with chemo-naive metastatic castration-resistant prostate cancer (mCRPC) |
| Meeting Title: | 2021 Genitourinary Cancers Symposium |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 39 |
| Issue: | 6 Suppl. |
| Meeting Dates: | 2021 Feb 11-13 |
| Meeting Location: | Virtual |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2021-02-20 |
| Language: | English |
| ACCESSION: | WOS:000636801500060 |
| DOI: | 10.1200/JCO.2021.39.6_suppl.9 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 9 -- Source: Wos |
